Biotech News
5.15.09 - Integrated BioTherapeutics Wins "2009 Emerging Company of the Year" at Tech Council of Maryland Annual Awards Celebration
The awards ceremony was held on May 14th at the Bethesda North Marriott Hotel & Convention Center, in Bethesda MD. Dr. M. Javad Aman, Founder and Chief Scientific Officer, received the prize on behalf of the company. Integrated BioTherapeutics, Inc. was one of five finalists in the category of “Emerging Company of the Year” 2009. The award is given to small businesses that have shown vision and enterprise in starting up and throught a well prepared business plan and market performance, are meeting targeted financial goals. A demonstrated ability to attract resources (awards, investments, revenues, or access to critical resources) is a criteria for award. IBT started its operations with a $50,000 grant from Maryland TEDCO in 2006 and since that time has raised over $30 million in government grants and contracts including a $22 million 4 year contract with NIAID to develop a panfilovirus vaccine which may reach $65 million if NIAID exercises all options under the award.
10.2.2008 - Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses
Vaccine Has Potential to Save Millions of Lives
GERMANTOWN, Md. - Integrated BioTherapeutics Inc. (IBT), a biotechnology company focused on development of medical countermeasures for biodefense and emerging infectious diseases, announced they have been awarded a multiyear contract for advanced development of a vaccine to protect against Ebola and Marburg viruses from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The contract is valued at approximately $22 million, which, if options are exercised, could total up to up $65 million.
Considered a significant bioterrorist threat, Ebola and Marburg lead to death 30-90 percent of the time they are contracted, and there are currently no vaccines or therapeutics available for treatment of humans infected with either virus. Ebola and Marburg virus outbreaks typically occur in resource poor areas in sub-saharan Africa, although rare cases have occurred in the United States, Europe and the Phillippines. Filoviruses are also a source of concern as potential bioterror agents.
“We are very pleased that NIAID has awarded such a significant contract to fund the advanced development activities for our virus-like particle vaccine against Ebola and Marburg viruses. This is a significant step forward in our mission to improving public health and developing medical countermeasures for biodefense. This contract will fund a major portion of the preclinical and clinical activities required to confirm and refine the activity in animals and verify the activity in humans,” commented Dr. Javad Aman, IBT President and Chief Scientific Officer.
IBT is collaborating with colleagues at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to develop a subunit vaccine, based on the virus-like particles, with broad-spectrum activity toward different strains of Ebola and Marburg viruses. Other collaborating organizations include Protein Sciences Corporation, Meriden, Conn.; Aridis Pharmaceuticals, San Jose, Calif.; Baylor College of Medicine, Houston, Tex.; and AMAR International, Fairfax, Va.
The ultimate objective of the government's program is to develop a safe and effective vaccine to protect against the Zaire, Sudan and Cote d'Ivoire strains of Ebola virus as well as multiple isolates of Marburg virus. The vaccine, to be developed by IBT, provides broad protection in nonhuman primates. The virus-like particle vaccines are strikingly similar to the authentic virus and were originally developed by IBT's founders and their colleagues at USAMRIID.
Initially, IBT will receive approximately $22 million to conduct preclinical activities, including preclinical efficacy animal studies, development and qualification of assays, formulation studies and process development for manufacturing activities. After preclinical studies, NIAID may exercise options to the contract that include cGMP manufacturing, Phase 1 clinical trial, scale-up of cGMP manufacturing, lyophylized formulation and a Phase 2 clinical trial The potential value of the entire contract if all the options are exercised by the government, is $65.2 million.
6.25.08 - IBT wins the "Incubator Company of the Year Award" 2008 as Best Life Science Company.
The purpose of the 2008 Maryland Incubator Company of the Year Awards is to publicly recognize achievements by current clients and graduates of Maryland incubators and to provide a forum for the nominees to increase their visibility in the business, technology and investment communities.
Integrated BioTherapeutics, Inc. (IBT) was nominated one of three finalists in the category “Best Life Science Company” this year. During the award ceremony held on June 10th at the Center Club in Baltimore, MD, IBT was announced as the winner of this year’s award. Dr. M. Javad Aman, Founder and Chief Scientific Officer, who received the prize, expressed IBT’s appreciation of the assistance received from TEDCO. IBT started its operations with a $50,000 grant from Maryland TEDCO in 2006 and has raised over 9 million dollars in government grants and contracts since then.
This award is in recognition of IBT’s great success over the last 3 years since its establishment in 2005.
- Maryland Incubator Company of the Year - Read Article
- Gazette - Read Article
- Frederick News Post - Read Article
- TechJournal South - Read Article
6.25.2008 - IBT moves to new location
Integrated BioTherapeutics, Inc. will move its laboratory and office space to Germantown, MD. The new location is in the same building as Avalon Pharmaceuticals, 20358 Seneca Meadows Parkway, Germantown, MD 20876. New phone numbers will be posted as soon as they are available. Until then please use the contact form (insert link) for inquiries.
6.25.2008 - IBT receives NIH grant
Integrated BioTherapeutics was awarded a $4.7M from NIH to continue research aimed at development of an immunotherapeutic against one of the toxins of Staphylococcus aureus. The work will be conducted in collaboration with the US Army Medical Research Institute of Infectious Diseases and ABD-Serotec/Morphosys, a German company with expertise in monoclonal antibody production.
5.5.2008
Integrated BioTherapeutics has been nominated one of three finalists for the “annual Maryland Incubator Company of the Year Awards” in the category “Life Science Companies”. This category comprises companies involved in the biotechnology or life sciences industry. The awards recognize the achievements of current and graduate companies within Maryland’s incubator network.
Companies are selected based on a number of factors. Criteria considered include:
- Success in achieving its objectives; its technology or product development
- Growth in revenue or earnings
- Number of customers and significant customers
- Technology transfer
- Attraction of outside investors
- Impact on the region
View PDF Article
10.1.2007
IBT received a phase I SBIR grant for development of human polyclonal antibody therapeutics against staphylococcal eneterotoxin B (SEB). SEB is classified as a category B select agent by the National Institutes of Health. SEB is also commonly produced by various strains of staphylococcus aureus including certain antibiotic resistant strains. SEB intoxication, as a result of exposure through bioterror dissemination or through natural infection, can cause severe toxic shock and cause incapacitation or death.
Through this project IBT intends to use its proprietary recombinant SEB vaccine (STEBVax) to develop human antibodies in healthy individuals. STEBVax is scheduled to enter into a clinical trial sponsored by National Institute of Allergy and Infectious Diseases (NIAID) in Spring 2008. IBT has entered into a collaborative relationship with Omrix Biopharmaceuticals for development of this therapeutic agent. Through this Phase I SBIR and in close coordination with Omrix Biopharmaceuticals IBT will develop all the required assays and methodologies for development of anti-SEB therapeutic in the Phase II of this SBIR.
7.3.2007
IBT received funding from the Defense Threat reduction Agency (DTRA) to test the safety of IBT's proprietary recombinant vaccine for staphylococcal enterotoxin B (STEBVax). This vaccine will be tested in rhesus monkeys to ensure its safety as a required step before moving into human clinical trials. STEBVax safety will be tested at Bridge Pharmaceuticals, Gaithersburg, MD, according to Good Laboratory Practice (GLP). IBT anticipates completing this study by January 2008 in anticipation of STEBVax clinical trial in Spring 2008.
